Initiation of a formalized precision medicine program in gynecologic oncology.
暂无分享,去创建一个
Robert S Mannel | R. Mannel | C. Gunderson | Kelsi Andrade | D Scott McMeekin | D. Mcmeekin | Camille C Gunderson | Kathleen N Moore | Michelle R Rowland | Deborah L Wright | Kelsi L Andrade | M. Rowland | K. Moore | Deborah Wright
[1] David Cameron,et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial , 2007, The Lancet.
[2] F. Collins,et al. Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.
[3] Jane Fridlyand,et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors , 2012, Nature.
[4] Gregory J Tsongalis,et al. Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center. , 2015, The oncologist.
[5] Amber M. Johnson,et al. A decision support framework for genomically informed investigational cancer therapy. , 2015, Journal of the National Cancer Institute.
[6] Steven J. M. Jones,et al. Integrated genomic characterization of endometrial carcinoma , 2013, Nature.
[7] Carlos Caldas,et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary , 2010, The Journal of pathology.
[8] Benjamin G. Bitler,et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers , 2015, Nature Medicine.
[9] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[10] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[11] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[12] Francisco Cervantes,et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.
[13] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[14] F. Collins,et al. A new initiative on precision medicine. , 2015, The New England journal of medicine.
[15] Edward S. Kim,et al. The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.
[16] Francisco Cervantes,et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.
[17] F. Vecchio,et al. HER-2 intratumoral heterogeneity , 2013, Modern Pathology.
[18] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[19] Razelle Kurzrock,et al. Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative , 2012, Clinical Cancer Research.
[20] Melonie P. Heron. Deaths: leading causes for 2010. , 2013, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[21] Eunyoung Kang,et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance , 2012, Modern Pathology.
[22] Daniel V.T. Catenacci,et al. Next‐generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity , 2014, Molecular oncology.